Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 8/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15070549 | 0.81 | CDA (0.49) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL16643735 | 0.81 | CDA (0.49) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL19402823 | 0.74 | CDA (0.41) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL22901482 | 0.74 | CDA (0.39) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL22901485 | 0.74 | CDA (0.39) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL6838533 | 0.73 | ADORA2A (0.39) | CDA | |
| SCHEMBL14178011 | 0.72 | EPHX2 (0.35) | CDA | |
| SCHEMBL14197686 | 0.72 | EPHX2 (0.35) | CDA | |
| SCHEMBL26311383 | 0.69 | CDA (0.48) | CDAPDE4DPDE3ASLC29A1 | |
| SCHEMBL12194530 | 0.68 | CDA (0.37) | CDAPDE4DPDE3ASLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073960-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | CDA 66/4885PDE4D 144/4885PDE3A 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.